THE ACUTE MORTALITY RESPONSE
OF MONKEYS (MACACA MULATTA)
TO MIXED GAMMA-NEUTRON RADIATIONS
AND 250 KVP X RAYS

Richard E. Stanley
Leslie J. Seigneur
Thomas A. Strike

ARMED FORCES RADIobiology RESEARCH INSTITUTE
Defense Atomic Support Agency
Bethesda, Maryland

Distribution of this document is unlimited.
This report has been approved for open publication by the Department of Defense

All aspects of investigative programs involving the use of laboratory animals sponsored by DOD components are conducted according to the principles enunciated in the "Guide for Laboratory Animal Facilities and Care", prepared by the National Academy of Sciences - National Research Council.
The mammalian responses to mixed gamma-neutron radiations are under intensive study at the Armed Forces Radiobiology Research Institute (AFRRI). The monkey (Macaca mulatta) has been the experimental animal of choice in several studies, particularly those concerned with incapacitation and behavioral decrements following lethal and superlethal exposures. The present study was undertaken as one essential phase of characterizing the lethal and clinical responses of the Macaca mulatta to mixed gamma-neutron radiations. Further, it represents an orderly progression, using various laboratory mammals, in evaluating median lethality from such radiations compared to a common reference source.

The monkeys were "wild-caught". They ranged in age from 2 to 5 years, weighed from 3.1 to 5.5 kilograms, and were equally distributed as to sex. Each animal had been conditioned for a minimum of 10 weeks and each had been tuberculin tested a minimum of five times. Beginning 2 weeks before irradiation and continuing throughout the 60-day postirradiation period, no therapeutic agents were administered. The basic diet was pelleted Purina monkey chow. The diet and frequency of feeding (3 times each day) were the same before and after irradiation. Food was available up to 1 hour before exposure.

The number of animals used in each part of the study is shown in Table 1. The x irradiations were accomplished with the radial beam of a 250 kVp x-ray generator. The AFRRI-TRIGA reactor was the source of the mixed gamma-neutron radiations. For simplicity of presentation, the mixed gamma-neutron radiations will be referred to as reactor radiations in the remainder of this report. Sixty animals were exposed to x rays and 80 to reactor radiations. Including controls, 80 animals were designated 1.
for x ray and 110 for the reactor radiations. A total of 190 animals was used in this study.

Table I. Total Animals

<table>
<thead>
<tr>
<th>Radiation field</th>
<th>Irradiated</th>
<th>Controls</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>x-ray</td>
<td>60</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>mixed gamma-neutron (reactor)</td>
<td>80</td>
<td>30</td>
<td>110</td>
</tr>
</tbody>
</table>

Six exposure points were used in x ray and 8 in the reactor radiations (Table II). Each exposure point consisted of 10 animals, simultaneously exposed. The exposure range in the x-ray facility was 380 to 665 rads and in the reactor radiations, 304 to 567 rads. The x-ray measured exposure in roentgens was converted to rads using the mean conversion factor (f) of 0.95 obtained from the International Commission on Radiological Units and Measurements (ICRU) Report 10b (National Bureau of Standards Handbook 85) for an x-ray generator with a tube potential of 250 kV and a HVL of 1.9 mm Cu.

Table II. Radiation Exposures

<table>
<thead>
<tr>
<th>Radiation field</th>
<th>Number of points</th>
<th>Exposure range</th>
</tr>
</thead>
<tbody>
<tr>
<td>x-ray</td>
<td>6*</td>
<td>380-665 rads</td>
</tr>
<tr>
<td>reactor</td>
<td>8*</td>
<td>304-567 rads</td>
</tr>
</tbody>
</table>

* 10 animals at each exposure point

Figure 1 illustrates the 10 positions on the circular exposure array in the x-ray facility. The room is 6 meters square. The source to midline exposure volume
THE ACUTE MORTALITY RESPONSE OF MONKEYS (MACACA MULATTA)
TO MIXED GAMMA–NEUTRON RADIATIONS AND 250 KVP X RAYS

RICHARD E. STANLEY
LESLEI J. SEIGNEUR
THOMAS A. STRIKE

Presented at the Third International Congress of Radiation Research,
Cortina, Italy, 26 June – 2 July 1966

ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE
Defense Atomic Support Agency
Bethesda, Maryland

Distribution of this document is unlimited.
distance was 105 centimeters. The x-ray generator was operated at 250 kilovolts and 30 milliamperes producing, with filtration, a HVL of 1.9 mm Cu (effective energy of 106 kilovolts). The dose rate in a Plexiglas phantom at the center of the exposure volume (pyramid-shaped restraint box) was 20 rads per minute.

Figure 1. Plan view of x-ray facility

Figure 2 shows the 10 positions on an isodose exposure arc in the reactor exposure room. This room is also 6 meters square. The distance from the reactor core centerline to the center of the exposure volumes was 400 centimeters. The dose rate in a Plexiglas phantom at the center of the exposure volumes was about 16 rads per minute. Sixty percent of the dose was gamma and 40 percent was neutron. The effective energy of the

Figure 2. Plan view of reactor exposure room
gamma was between 1 and 2 MeV. About 75 percent of the neutron dose was attributed to fast neutrons (greater than 10 keV). The remaining 25 percent was from neutrons of lower energies.

Figure 3 shows the animals in the circular exposure array in the x-ray facility. Seven of the 10 animals are visible. The Plexiglas restraint box was clamped to a turntable, the latter being mounted on a wood stand. Each turntable was individually...
driven by a small electric motor at 1 revolution per minute. Each restraint box was tilted 22-1/2 degrees to confine the dose falloff of the isodose exposure field to not more than 5 percent. A Victoreen Rate Meter was used to monitor each exposure. Dosimetry was accomplished in a Plexiglas phantom in these exposure positions.

Ten animals are shown in the reactor radiations exposure room (Figure 4). The mechanical arrangements for animal restraint and rotation were the same as shown in the x-ray facility, except for the tilt. In this exposure room, tilt was not required due to the more uniform isodose field. Extensive dosimetry was used in each exposure.
The paired ionization chambers as seen on the far left were used for radiation monitoring. Sulfur tablets were placed on the front of each stand and shielded glass rods on the first, fifth and tenth stands as additional monitors. Dosimetry was also accomplished in these exposure positions using the monkey phantom.

All exposures in this study are reported as midline phantom, referenced to the center of a Plexiglas phantom, cylindrical in shape, that was placed in the center of the pyramid-shaped restraint box (exposure volume). Figure 5 illustrates the dose profiles for the two radiation fields in the phantom expressed as percent of midline phantom. Distance from surface to midline of the phantom at the chest level is shown in centimeters. Because there is a centerline of symmetry in the phantom, the data are presented for one side. Both exposures were "Class A, uniform," as defined in ICRU Report 10e (National Bureau of Standards Handbook 88).

Table III presents the raw data 60-day percent mortalities. In the x-ray exposures, 380 rads was the 10 percent mortality point and 665 rads was the 90 percent mortality point. Four additional mortality points were obtained in the interval between
the 10 and 90 percent points. In the reactor radiations exposures, 304 rads was the 10 percent point and 515 rads was the 90 percent point. Five additional points were obtained in the 304 to 515 rads lethal exposure interval. The 567 rads reactor radiations exposure caused 100 percent mortality. There was no mortality in the 50 controls.

Table III. Mortalities

<table>
<thead>
<tr>
<th>Radiation field</th>
<th>10 percent point</th>
<th>Exposure points between</th>
<th>90 percent point</th>
</tr>
</thead>
<tbody>
<tr>
<td>x-ray</td>
<td>380 rads</td>
<td>4</td>
<td>665 rads</td>
</tr>
<tr>
<td>reactor</td>
<td>304 rads</td>
<td>5</td>
<td>515 rads</td>
</tr>
</tbody>
</table>

100 percent mortality in the 567 rads reactor radiations exposure

No control mortality

The data were analyzed with an IBM 1620 Computer using a probit program developed by the United States Department of Agriculture. Figure 6 illustrates the computed results, with percent mortality shown on the ordinate and dose on the

Figure 6. Dose-mortality regression lines
abscissa. The dose-response regression line for reactor radiations and the raw data points are shown as well as the x-ray regression line and the raw data points.

Table IV shows the 60-day median lethal doses for x-ray and reactor radiations as obtained from the data analyses. The computed 50 percent lethal dose for x-ray exposures was 503 rads and for reactor radiations, 381 rads. The corresponding 95 percent confidence limits are also shown. The Relative Biological Effectiveness (RBE) of the reactor radiations to produce acute mortality, under the conditions of this study, is calculated to be 1.3 (95 percent confidence limits of 1.1-1.5).

Table IV. Median Lethality Data

<table>
<thead>
<tr>
<th>Radiation field</th>
<th>60-day median lethal dose</th>
<th>95 percent confidence limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>x-ray</td>
<td>503 rads</td>
<td>448-546 rads</td>
</tr>
<tr>
<td>reactor*</td>
<td>381 rads</td>
<td>365-408 rads</td>
</tr>
</tbody>
</table>

* RBE of 1.3

Table V shows the comparability of mortality distributions in the two lethal ranges (excluding the superlethal 567-rad dose group). Of the 35 mortalities from x-ray exposures, 31 occurred in the 10 to 19-day interval. Thirty-six of the 37 mortalities from reactor radiations exposures occurred in that same interval. No deaths occurred after 30 days.

Vomiting occurred in 135 of the 140 irradiated animals in the 72 hours immediately following irradiation. One hundred and thirty-two had vomited one or more times by the end of the 3rd hour. Other early postirradiation symptoms were
polydipsia, anorexia, and diarrhea. Integumentary petechiations were observed in most animals, beginning about the 10th day. Epilation was seen in about 25 percent of the animals. Marked ulcerative lesions on the labial and buccal mucosa and on the dorsum of the tongue were found in some animals.

Table V. Mortality Distributions

<table>
<thead>
<tr>
<th>Radiation field</th>
<th>Total mortality</th>
<th>Intervals of deaths (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0-9</td>
</tr>
<tr>
<td>x-ray</td>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>reactor</td>
<td>37</td>
<td>0</td>
</tr>
</tbody>
</table>

* No deaths after 30 days

Each decedent in this study was necropsied. Hemorrhage and evidences of infection were the most prominent gross changes seen. Petechial hemorrhages were almost invariably found in the integument, gastrointestinal tract, and selected major organs. Diffuse subendocardial and myocardial hemorrhages were seen in the left heart of most of the animals. A representative listing of lesions associated with infection is as follows:

- Ulceration of the oral cavity and of the cecal and colonic mucosa.
- Pulmonary adhesions and pneumonias.
- Occasional pustular abscesses in the major organs.
CONCLUSIONS

Under the conditions of this study, it was concluded that for the Macaca mulatta:

- The median lethal dose is 503 rads for x rays and 381 rads for reactor radiations.
- The acute mortality RBE of reactor radiations as determined by the ratio of midlethal doses measured at the midline of a homogeneous Plexiglas phantom was 1.3.
- Acute radiation death from lethal range x-ray or reactor radiations exposures will almost invariably occur between the 10th and 20th postirradiation day.
- Deaths from lethal range exposures will rarely occur in the 30 to 60-day postirradiation interval.
- Vomiting usually occurs within 3 hours after irradiation of the nonfasted monkey.
- Radiation quality differences were not discernible in the mode of death, survival time, clinical symptoms, or gross pathology.
REFERENCES


DISTRIBUTION LIST

AIR FORCE
Executive Officer, Director of Professional Services, Office of the Surgeon General, Hq. USAF (AFMSPA) T-8, Washington, D. C. 20333 (1)
Headquarters, U. S. Air Force (AFMSPAB), Washington, D. C. 20333 (1)
Chief, Radiobiology Branch, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks AFB, Texas 78235 (2)
Chief, Weapons and Weapons Effects Division, Hq. RTD (RTTW), Bolling AFB, Washington, D. C. 20332 (1)
Air Force Weapons Laboratory, ATTN: WLIL (1), ATTN: WLRB-2 (1), Kirtland AFB, New Mexico 87117 (2)
Chief, Nuclear Medicine Department, P. O. Box 5088, USAF Hospital Wright-Patterson, Wright-Patterson AFB, Ohio 45433 (1)

ARMY
The Surgeon General, U. S. Department of the Army, Washington, D. C. 20315 (1)
USACDC CSSG, Doctrine Division, Fort Lee, Virginia 23801 (1)
Commanding Officer, USACDC CBR Agency, Fort McClellan, Alabama 36021 (1)
Commanding Officer, U. S. Army Combat Developments Command, Institute of Nuclear Studies, Fort Bliss, Texas 79916 (1)
CG, USCONARC, ATTN: ATUTR-TNG (NBC), Fort Monroe, Virginia 23651 (1)
Commanding Officer, Harry Diamond Laboratories, ATTN: Nuclear Vulnerability Branch, Washington, D. C. 20438 (1)
Commanding Officer, U. S. Army Medical Research Laboratory, Fort Knox, Kentucky 40121 (1)
Commanding Officer, USA Nuclear Medical Research Detachment, Europe, APO New York, New York 09180 (2)
Chief of Research and Development, ATTN: Nuclear, Chemical and Biological Division, U. S. Department of the Army, Washington, D. C. 20310 (1)
Army Research Office, ATTN: Chief, Scientific Analysis Branch, Life Sciences Division, 3045 Columbia Pike, Arlington, Virginia 22204 (1)
Division of Nuclear Medicine, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D. C. 20012 (6)

NAVY
Chief, Bureau of Medicine and Surgery, U. S. Navy Department, Washington, D. C. 20390 (1)
Commanding Officer and Director (222A), U. S. Naval Radiological Defense Laboratory, San Francisco, California 94135 (2)
Head, Division of Biology and Medicine, U. S. Naval Radiological Defense Laboratory, San Francisco, California 94135 (1)
Commanding Officer, Naval Aerospace Medical Institute, Naval Aviation Medical Center, ATTN: Director of Research, Pensacola, Florida 32512 (3)
Commanding Officer, Nuclear Weapons Training Center, Atlantic, Nuclear Warfare Department, Norfolk, Virginia 23511 (1)
Commanding Officer, Nuclear Weapons Training Center, Pacific, U. S. Naval Air Station, North Island, San Diego, California 92135 (1)
Director, Biological Sciences Division, Office of Naval Research, Washington, D. C. 20360 (1)
Commanding Officer, U. S. Naval Hospital, ATTN: Director, REEL, National Naval Medical Center, Bethesda, Maryland 20014 (1)

D.O.D.
Director, Defense Atomic Support Agency, Washington, D. C. 20301 (1)
Deputy Director, Defense Atomic Support Agency, Washington, D. C. 20301 (1)
Director, Defense Atomic Support Agency, ATTN: Chief, Medical Division, Washington, D. C. 20301 (1)
Director, Defense Atomic Support Agency, ATTN: Chief, Radiation Division, Washington, D. C. 20301 (1)
Director, Defense Atomic Support Agency, ATTN: Document Library Section, Washington, D. C. 20301 (1)
Commander, Field Command, Defense Atomic Support Agency, ATTN: FC Technical Library, Sandia Base, Albuquerque, New Mexico 87115 (1)
Director, Armed Forces Institute of Pathology, Washington, D. C. 20305 (1)
Administrator, Defense Documentation Center, Cameron Station, Bldg. 5, Alexandria, Virginia 22314 (20)
OTHER (continued)

Western Reserve University, Department of Radiology, Division of Radiation Biology, Cleveland, Ohio 44106 (1)
Texas Nuclear Corporation, ATTN: Director of Research, Box 9267 Allandale Station, Austin, Texas 78756 (1)

FOREIGN

Dr. G. W. Barendsen, Radiobiological Institute TNO, Rijswijk, Netherlands (1)
Dr. H. Cottier, Pathological Institut der Universitat, Bern, Switzerland (1)
Dr. M. Feldman, Section of Cell Biology, The Weizmann Institute of Science, Rehovoth, Israel (1)
International Atomic Energy Agency, Kaerntnerring 11, Vienna I. 1010, Austria (1)
Dr. L. G. Lajtha, Paterson Laboratories, Christie Hospital and Holt Radium Inst., Manchester, England (1)
Dr. L. F. Lamerton, Biophysics Department, Institute of Cancer Research, Surrey Branch, Belmont, Sutton, Surrey, England (1)
Dr. Helmut Mitschrich, Academie des Sanitaets-und Gesundheits, Weseus BW, Spezialstab ATV, 8 Muenchen, Schwere-Reiterstr. 4, Germany (2)
Puerto Rico Nuclear Center, ATTN: Reading Room, College Station, Mayaguez, Puerto Rico 00703 (2)
Dr. L. M. van Putten, Radiobiological Institute TNO, 151 Lance Kleiweg, Rijswijk 2 H., Netherlands (1)
Directorate of Medical and Health Services, FAF (Federal Armed Forces), Bonn, Ermekeilstr. 27, West Germany (1)
One hundred and forty young adult male and female monkeys (Macaca mulatta) were irradiated with single whole-body doses of mixed gamma-neutron radiations or 250 kVp x rays. The 80 mixed gamma-neutron and 60 x irradiated animals were uniformly exposed in groups of 10 to graded doses delivered at the rate of 16 and 20 rads per minute respectively while being slowly rotated in an upright position. Referenced to the midline of a Plexiglas monkey phantom, LD50/60 values of 503 ± 20 rads and 381 ± 13.5 rads were calculated for x-ray and mixed gamma-neutron radiations, respectively. Using 250 kVp x ray as the reference source, the acute mortality Relative Biological Effectiveness of mixed gamma-neutron radiations as determined by the ratio of midline rad doses in a Plexiglas phantom was 1.3.

Ninety-three percent of the deaths occurred in the 10 - 19-day interval resulting in a mean survival time of approximately 15 days with no deaths occurring after 28 days.

From the comparative data on clinical observations, survival time, gross pathology of the decedents and serial hemograms of the survivors during the 30 - 60-day intervals, no significant difference in response was apparent in the x- or mixed gamma-neutron irradiated monkey. Further, death, with one exception, was concluded to be principally attributable to hematopoietic injury with infection as the major contributing lethal factor.
radiation
RBE
Macaca mulatta
lethality, median
acute mortality

<table>
<thead>
<tr>
<th>KEY WORDS</th>
<th>LINK A</th>
<th>LINK B</th>
<th>LINK C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ROLE</td>
<td>WT</td>
<td>ROLE</td>
</tr>
</tbody>
</table>

1. ORIGINATING ACTIVITY: Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (corporate author) issuing the report.

2a. REPORT SECURITY CLASSIFICATION: Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

2b. GROUP: Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.

3. REPORT TITLE: Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parenthesis immediately following the title.

4. DESCRIPTIVE NOTES: If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.

5. AUTHOR(S): Enter the name(s) of author(s) as shown on the report. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.

6. REPORT DATE: Enter the date of the report as day, month, year, or month, year. If more than one date appears on the report, use date of publication.

7a. TOTAL NUMBER OF PAGES: The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

7b. NUMBER OF REFERENCES: Enter the total number of references cited in the report.

8a. CONTRACT OR GRANT NUMBER: If appropriate, enter the applicable number of the contract or grant under which the report was written.

8b, 8c, & 8d. PROJECT NUMBER: Enter the appropriate military department identification, such as project number, subproject number, system numbers, task number, etc.

9a. ORIGINATOR'S REPORT NUMBER(S): Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.

9b. OTHER REPORT NUMBERS: If the report has been assigned any other report numbers (either by the originator or by the sponsor), also enter this number(s).

10. AVAILABILITY/LIMITATION NOTICES: Enter any limitations on further dissemination of the report, other than those imposed by security classification, using standard statements such as:

   (1) "Qualified requesters may obtain copies of this report from DDC."
   (2) "Foreign announcement and dissemination of this report by DDC is not authorized."
   (3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through...
   (4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through...
   (5) "All distribution of this report is controlled. Qualified DDC users shall request through..."

   If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. SUPPLEMENTARY NOTES: Use for additional explanatory notes.

12. SPONSORING MILITARY ACTIVITY: Enter the name of the departmental project office or laboratory sponsoring the research and development. Include address.

13. ABSTRACT: Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

   It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS), (S), (C), or (U).

   There is no limitation on the length of the abstract. However, the suggested length is from 100 to 225 words.

14. KEY WORDS: Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context. The assignment of links, rules, and weights is optional.